A prospective, observational, multicenter study on risk factors and prophylaxis for low emetic risk chemotherapy-induced nausea and vomiting.
The incidence of and the risk factors for nausea and vomiting in patients undergoing low emetic risk chemotherapy (LEC) are unclear. The aim of the study was to provide information on these topics by performing a multicenter, observational, prospective study.



The study consisted of patients who were administered first-time LEC that was consistent or inconsistent with current guidelines. Using the visual analog scale, patients recorded their daily food intake and the occurrence and severity of nausea over a 5-day treatment period.



The overall incidence of chemotherapy-induced nausea and vomiting did not differ significantly between patients undergoing guideline-consistent (n = 89) or guideline-inconsistent (n = 121) prophylaxis (30.3 vs. 22.3%, respectively; P = 0.19). Logistic regression analysis identified a history of nausea and LEC other than taxanes as independent risk factors associated with nausea and vomiting in patients undergoing LEC. The mean daily visual analog scale scores for nausea severity and a decrease in food intake were <25 mm throughout the entire observation period.



Guideline-consistent prophylaxis appeared to control nausea and vomiting effectively in patients undergoing LEC. However, patients with a history of nausea and receiving LEC other than taxanes should be carefully observed and treatment should be adjusted according to their symptoms.
Department of Pharmacy, Clinical Research Institute, National Kyushu Medical Center, 1-8-1, Jigyohama, Chuo-ku, Fukuoka, 810-8563, Japan. nenten-ph@umin.org.|Department of Pharmacy, National Kyushu Cancer Center, 3-1-1, Notame, Minami-ku, Fukuoka, 811-1395, Japan. nenten-ph@umin.org.
Toshinobu
0000-0001-6183-4939
T
Hayashi
Cancer Biostatistics Laboratory, Clinical Research Institute, National Kyushu Cancer Center, 3-1-1, Notame, Minami-ku, Fukuoka, 811-1395, Japan.
Mototsugu
M
Shimokawa
Department of Pharmacy, National Hospital Organization Beppu Medical Center, 1473 Uchikamado, Beppu, Oita, 874-0011, Japan.
Takanori
T
Miyoshi
Department of Pharmacy, National Hospital Organization Beppu Medical Center, 1473 Uchikamado, Beppu, Oita, 874-0011, Japan.
Yoko
Y
Toriyama
Department of Pharmacy, National Hospital Organization Nagasaki Medical Center, 2-1001-1 Kubara, Omura, Nagasaki, 856-8562, Japan.
Chiaki
C
Yokota
Department of Pharmacy, National Hospital Organization Ureshino Medical Center, 2436 Oazashimojukuhei, Ureshino-cho, Ureshino, Saga, 843-0393, Japan.
Jun
J
Taniguchi
Department of Pharmacy, National Hospital Organization Kumamoto Saishunso National Hospital, 2659 Suya, Koushi, Kumamoto, 861-1196, Japan.
Kiyonori
K
Hanada
Department of Pharmacy, National Hospital Organization Miyakonojo Medical Center, 5033-1 Iwayoshi-cho, Miyakonojo, Miyazaki, 885-0014, Japan.
Kyouichi
K
Tsumagari
Department of Pharmacy, National Hospital Organization Kumamoto Medical Center, 1-5 Ninomaru, Chuo-ku, Kumamoto, 860-0008, Japan.
Noriko
N
Okubo
Department of Pharmacy, National Hospital Organization Fukuoka National Hospital, 1-39-4, Yakatabaru, Minami-ku, Fukuoka, 811-1394, Japan.
Yoshimichi
Y
Koutake
Department of Pharmacy, National Hospital Organization Kumamoto South National Hospital, 2338 Toyofuku, Matsubase-cho, Uki, Kumamoto, 869-0593, Japan.
Kohei
K
Sakata
Department of Pharmacy, National Hospital Organization Kagoshima Medical Center, 8-1, Shiroyama-cho, Kagoshima, 892-0853, Japan.
Yosei
Y
Kawamata
Department of Pharmacy, National Hospital Organization Kokura Medical Center, 10-1, Harugaoka, Kokuraminami-ku, Kitakyushu, 802-8533, Japan.
Takashi
T
Goto
Department of Pharmacy, National Hospital Organization Saga National Hospital, 1-20-1, Hinode, Saga, 849-8577, Japan.
Yasufumi
Y
Tsurusaki
Department of Pharmacy, Clinical Research Institute, National Kyushu Medical Center, 1-8-1, Jigyohama, Chuo-ku, Fukuoka, 810-8563, Japan.
Makiko
M
Koyabu
D000368:Aged; D000932:Antiemetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced*; D011446:Prospective Studies; D012307:Risk Factors; D014839:Vomiting / Q000139:chemically induced*
D000932:Antiemetics; D000970:Antineoplastic Agents
Chemotherapy-induced nausea and vomiting; Low emetic risk chemotherapy; Nausea; Risk factors; Vomiting